Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of ALT-801 in Healthy Overweight and Obese Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pemvidutide (Primary)
Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors Altimmune

Most Recent Events

07 Nov 2022 Results (n= 34) assessing the effects of pemvidutide on other lipid mediators implicated in atherosclerosis and metabolic syndrome presented at the American Heart Association Scientific Sessions 2022
26 Jun 2022 Results presented at The International Liver Congress 2022
01 Apr 2022 Results published in an Altimmune media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com